Crinetics Pharmaceuticals, Inc.
CRNX
주식 순위
#2248
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
주가
$84.95
마지막 동기화: 2026-09-01
시가총액
$9.00B
변동 (1일)
0.00%
변동 (1년)
100.12%
국가
US
거래 Crinetics Pharmaceuticals, Inc. (CRNX)
카테고리
Healthcare
Crinetics Pharmaceuticals, Inc. (CRNX)의 배당 수익률 기록
Crinetics Pharmaceuticals, Inc. (주식 심볼: CRNX)의 배당 수익률 (TTM)은 2023-12-31 기준으로 0.00%입니다.
지난 5년 평균 배당 수익률: 0.00%
지난 5년 평균 배당 수익률: 0.00%
Crinetics Pharmaceuticals, Inc. (CRNX)의 배당 수익률 기록: 2016 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
| 연도 | 배당 수익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
유사 기업 또는 경쟁사의 배당 수익률 (TTM)
| 회사 | 배당 수익률 | 국가 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
